NAION and GLP-1 Medications: What Patients Should Know About This Rare Eye Complication
Understanding the potential association between GLP-1 medications and a rare condition that can cause sudden, permanent vision loss.
Patient Education | Mark M. de Carvalho MSN, APRN, FNP-C | RealCare Wellness

What is NAION?
Non-arteritic anterior ischemic optic neuropathy (NAION) is a rare eye condition that occurs when blood flow to the front portion of the optic nerve becomes reduced or interrupted.
The optic nerve is responsible for transmitting visual information from the eye to the brain. When its blood supply is compromised, the nerve can become damaged, potentially resulting in permanent vision loss.
NAION is one of the most common causes of sudden optic nerve-related vision loss in adults over age 50. Although it typically affects one eye, the other eye can also become affected.
Unlike some other eye conditions, NAION generally develops suddenly and without pain. Some patients first notice a change in their vision when they wake up in the morning.
Importantly, there is currently no established treatment that reliably reverses the optic nerve damage caused by NAION.
Source: American Academy of Ophthalmology; North American Neuro-Ophthalmology Society.
What is the connection between NAION and GLP-1 medications?
GLP-1 receptor agonists have become widely used medications for managing type 2 diabetes and obesity. These medications work by mimicking the naturally occurring glucagon-like peptide-1 hormone, helping regulate blood glucose, appetite, and satiety.
Examples include:
Semaglutide: Ozempic and Wegovy
Liraglutide: Saxenda and Victoza
Dulaglutide: Trulicity
Exenatide: Byetta and Bydureon
Tirzepatide: Mounjaro and Zepbound (a dual GIP/GLP-1 receptor agonist)
In recent years, researchers have investigated whether semaglutide and other GLP-1-based medications may be associated with an increased risk of NAION.
The concern initially gained attention following a 2024 study published in JAMA Ophthalmology. Researchers at Mass Eye and Ear examined medical records and found an association between semaglutide prescriptions and an increased risk of NAION.
Subsequent studies have produced mixed findings, prompting further investigation by international regulatory agencies.
What have regulatory agencies found?
1. European Medicines Agency (EMA) – June 2025
The EMA's Pharmacovigilance Risk Assessment Committee (PRAC) concluded that NAION should be classified as a very rare side effect of semaglutide-containing medications, including Ozempic, Wegovy, and Rybelsus.
The agency estimated that NAION may affect up to 1 in 10,000 people taking semaglutide.
The EMA recommended that patients experiencing sudden vision loss or rapidly worsening eyesight seek medical attention immediately. If NAION is confirmed, semaglutide treatment should be discontinued.
2. World Health Organization (WHO) – June 2025
The WHO issued a medical product alert following the EMA's findings, notifying healthcare professionals and regulatory authorities about the potential association between semaglutide and NAION.
3. U.S. Food and Drug Administration (FDA) – November 2026
On November 9, 2026, the FDA announced that it would require updated safety labeling for GLP-1 receptor agonist medications to include information about the potential increased risk of NAION.
The FDA reviewed clinical trial data involving 126 randomized controlled trials and more than 134,000 participants.
Its analysis identified:
6.4 NAION cases per 100,000 person-years among GLP-1 users.
3.8 NAION cases per 100,000 person-years among comparator-treated patients.
The FDA also conducted a real-world analysis involving adults with type 2 diabetes. Findings suggested a higher risk compared with certain alternative diabetes medications, although the results varied depending on the comparator.
The FDA concluded that there is a potential increased risk of rare NAION events associated with GLP-1 medications.
This is an important development because the safety concern is no longer limited to academic research or isolated case reports. It has prompted a formal regulatory response.
How common is NAION among GLP-1 users?
It is important to put this potential complication into perspective.
NAION is already a rare condition, even among people who do not take GLP-1 medications.
The FDA cites an estimated annual incidence of approximately 2.3 to 10.2 cases per 100,000 adults over age 50 in the general population.
The EMA classifies NAION associated with semaglutide as very rare, meaning it may affect up to 1 in 10,000 users.
These figures should not be interpreted as proof that every patient taking a GLP-1 medication has an increased risk. They represent different populations, study methods, and estimates.
The available evidence suggests that the absolute risk remains low. However, because the potential outcome can involve permanent vision loss, awareness and early recognition are important.
What are the warning signs and symptoms?
NAION typically presents with sudden, painless changes in vision, usually affecting one eye.
Watch for the following symptoms:
Sudden blurred or reduced vision in one eye.
A dark or missing area in the visual field.
Difficulty seeing objects in the upper or lower portion of your vision.
Sudden dimming or haziness of vision.
Changes in color perception.
A noticeable reduction in central or peripheral vision.
Vision changes first noticed upon waking.
Important: NAION does not typically cause eye pain. The absence of pain does not mean the condition is less serious.
If you experience sudden vision loss or a new visual field defect, seek emergency medical evaluation immediately. Do not wait for your next scheduled appointment or assume the symptoms will resolve on their own.
An ophthalmologist or neuro-ophthalmologist can perform the necessary examination to determine the cause.
Who may be at higher risk?
NAION is associated with several underlying medical and anatomical risk factors.
These include:
Type 2 diabetes or impaired glucose regulation.
High blood pressure.
High cholesterol.
Obstructive sleep apnea (OSA).
Smoking.
Cardiovascular disease.
Anemia.
Certain anatomical characteristics of the optic nerve, particularly a small or crowded optic disc.
Some of these conditions are also common among individuals receiving GLP-1 medications for diabetes and weight management.
This creates an important consideration when interpreting research: patients taking GLP-1 medications may already have underlying conditions that increase their baseline risk of NAION.
Consequently, researchers must distinguish between the potential effects of a medication and the effects of the patient's underlying health conditions.
Does this mean I should stop taking my GLP-1 medication?
No. Patients should not independently discontinue their prescribed medication solely because of concerns about NAION.
GLP-1 medications have demonstrated important benefits in appropriate patients, including:
Improved blood glucose control.
Clinically meaningful weight reduction.
Improvements in several cardiometabolic risk factors.
Cardiovascular and kidney benefits with certain medications in specific patient populations.
For many individuals, the benefits of treatment may substantially outweigh the potential risks.
However, medication decisions should always consider the patient's individual medical history, underlying conditions, treatment goals, and potential adverse effects.
If you have concerns about NAION, discuss them with your prescribing healthcare professional.
If you have previously experienced NAION or unexplained vision loss, make sure your prescribing clinician is aware of this history before starting or continuing treatment.
If NAION is suspected or confirmed, urgent ophthalmologic evaluation and an individualized medication review are necessary. The FDA advises clinicians to consider discontinuing GLP-1 therapy in patients who develop NAION unless the benefits clearly outweigh the risks. The EMA specifically recommends stopping semaglutide if NAION is confirmed.
Can NAION be prevented?
Unfortunately, there is currently no proven method that completely prevents NAION.
However, patients can take steps to manage several associated health risks:
1. Maintain good blood pressure control.
Work with your healthcare professional to maintain appropriate blood pressure levels. Avoid independently changing your blood pressure medication schedule.
2. Manage blood glucose levels.
Good diabetes management is important for reducing long-term vascular complications.
3. Address obstructive sleep apnea.
If you have been diagnosed with sleep apnea, follow your prescribed treatment plan. Patients using CPAP should maintain adherence and follow up with their sleep medicine provider.
4. Manage cholesterol levels.
Follow appropriate treatment recommendations for dyslipidemia and cardiovascular risk reduction.
5. Avoid smoking.
Smoking contributes to vascular injury and is a recognized risk factor for NAION.
6. Report visual changes immediately.
Early evaluation is essential because sudden vision changes may represent a serious ophthalmologic or vascular emergency.
These measures support overall vascular health but cannot guarantee prevention of NAION.
Are all GLP-1 medications associated with NAION?
This is an important question that researchers are still investigating.
The strongest regulatory evidence and formal safety classification currently concern semaglutide.
However, the FDA's November 2026 safety communication addresses the potential risk across the GLP-1 receptor agonist class.
Tirzepatide, marketed as Mounjaro and Zepbound, is technically a dual GIP/GLP-1 receptor agonist rather than a conventional GLP-1 receptor agonist alone.
The American Academy of Ophthalmology and the North American Neuro-Ophthalmology Society have emphasized that evidence regarding other medications in this therapeutic class remains insufficient to determine whether the possible increased risk is specific to semaglutide or extends to other agents.
Therefore, it would be premature to conclude that switching from one medication to another eliminates the potential risk.
What should patients remember?
GLP-1 medications have changed the management of obesity and metabolic disease, providing meaningful health benefits for many patients.
Like all medications, however, they carry potential risks that deserve attention.
NAION is a rare but serious condition that can cause sudden and potentially permanent vision loss. Emerging research and regulatory reviews have identified a possible association with GLP-1-based therapies, particularly semaglutide.
The goal is not to discourage patients from receiving appropriate treatment. Rather, it is to promote informed decision-making, responsible prescribing, and early recognition of potential complications.
If you are taking a GLP-1 medication and experience sudden, painless vision changes, seek emergency medical evaluation immediately. Protecting your vision should never wait.
At RealCare Wellness, we believe that effective medical weight management involves more than achieving a number on the scale. It requires individualized treatment, ongoing monitoring, patient education, and an understanding of both the benefits and potential risks of medical therapy.
Medical Disclaimer
The information provided by RealCare Wellness is intended for general educational and informational purposes and reflects available medical evidence at the time of publication. It is not intended to replace individualized medical advice, diagnosis, or treatment.
Although this content is developed with clinical knowledge and evidence-based medical references, individual healthcare decisions should be made in consultation with a qualified healthcare professional familiar with your medical history.
Do not start, discontinue, or modify prescribed medications without consulting your healthcare provider. If you experience sudden vision loss or other acute visual changes, seek immediate emergency medical evaluation.
References and Further Reading
U.S. Food and Drug Administration (FDA). (November 9, 2026). FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists Due to Potential Increased Risk of Rare But Serious Eye Condition.https://www.fda.gov/drugs/drug-safety-communications
American Academy of Ophthalmology (AAO) and North American Neuro-Ophthalmology Society (NANOS). (2026). Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Non-Arteritic Anterior Ischemic Optic Neuropathy: A Consensus Statement.https://www.aao.org/education/clinical-statement/glucagon-like-peptide-1-receptor-agonists-risk-of-
European Medicines Agency (EMA). (June 6, 2025). PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines Ozempic, Rybelsus and Wegovy.https://www.ema.europa.eu/en/news/prac-concludes-eye-condition-naion-very-rare-side-effect-semaglutide-medicines-ozempic-rybelsus-wegovy
World Health Organization (WHO). (June 27, 2025). The use of semaglutide medicines and risk of non-arteritic anterior ischemic optic neuropathy (NAION).https://www.who.int/news/item/27-06-2025-27-06-2025-semaglutide-medicines-naion
Hathaway JT, et al. (2024). Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide. JAMA Ophthalmology, 142(8), 732–739.https://doi.org/10.1001/jamaophthalmol.2024.2296
Wu KY, Evoy F. (2022). NAION: Diagnosis and Management. American Academy of Ophthalmology.https://www.aao.org/eyenet/article/naion-diagnosis-and-management
North American Neuro-Ophthalmology Society (NANOS). Non-Arteritic Anterior Ischemic Optic Neuropathy: Patient Information.https://www.nanosweb.org/naion
American Academy of Ophthalmology. (2026). Semaglutide and the Risk of Nonarteritic Ischemic Optic Neuropathy: A Systematic Review and Certainty of Evidence Meta-Analysis.https://doi.org/10.1016/j.ophtha.2026.02.013
Last reviewed: November 2026.
.png)


Comments